To our knowledge, this case represents the first published report detailing the use of a combination osimertinib and fam-trastuzumab-deruxtecan for the treatment of EGFR and HER2-mutated NSCLC after progression on osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.